Medpace price to sales ratio MEDP
Market value divided by revenue over the last twelve months, since 2017.
- Today, Nov 2, 2026
- 6.5×
- 9-year median
- 4.7×
- Against its 9-year history
- 88th
- percentile: 0 is its lowest day, 100 its highest
- 9-year range
- 2.6× to 7.5×
- Peer median
- 6.3×
Medpace's price to sales ratio is 6.5× as of Nov 2, 2026.
That is above its 9-year median of 4.7×, higher than on 88% of days in the last 9 years.
Over that time it ranged from 2.6× in May 2019 to 7.5× in Nov 2021.
The median for 10 diagnostics and research stocks of a similar size is 6.3×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 6.5× | 4.4× | 7.3× |
| 2025 | 6.8× | 3.9× | 7.2× |
| 2024 | 5.1× | 4.7× | 7.0× |
| 2023 | 5.3× | 3.7× | 5.4× |
| 2022 | 4.8× | 3.5× | 6.2× |
| 2021 | 7.2× | 5.3× | 7.5× |
| 2020 | 5.6× | 2.8× | 5.6× |
| 2019 | 3.7× | 2.6× | 4.0× |
| 2018 | 2.9× | 2.7× | 4.0× |
| 2017 | 3.2× | 2.8× | 3.2× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Medpace's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| MEDPMedpace | 6.5× |
| RVTYRevvity | 5.8× |
| DGXQuest Diagnostics | 2.3× |
| LHLabcorp | 2.0× |
| BIOBio-Rad Laboratories | 3.8× |
| MTDMettler-Toledo International | 8.3× |
| ILMNIllumina | 8.0× |
| CAICaris Life Sciences | 9.2× |
| IQVIQVIA | 2.5× |
| WATWaters | 10.0× |
| AAgilent Technologies | 6.7× |
| Peer median | 6.3× |
Where Medpace ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Medpace
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.